// App-Quantinova.ai

4746 : Pharmacological characterization of BAY-876, a novel highly selective inhibitor of glucose transporter (GLUT)-1 in vitro and in vivo

Researchers

Presenter

  • Charlotte Kopitz

Principal Investigators

  • Luisella Toschi

  • Carolyn Algire

  • Melanie Heroult

  • Anna-Lena Frisk

  • Kirstin Meyer

  • Arndt Schmitz

  • Eleni Lagkadinou

  • Heike Petrul

  • Iring Heisler

  • Roland Neuhaus

  • Bernd Buchmann

  • Herbert Himmel

  • Marcus Bauser

  • Andrea Haegebarth

  • Karl Ziegelbauer

Medical Centers

  • Bayer, Berlin, Germany

  • Bayer AG, Leverkusen, Germany

  • Bayer Pharma AG, Berlin, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Hypoxia-inducible factor-1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved